{"i": ["OXC - IR ( Trileptal )", "ER ) OXC", "b . i . d .", "lamotrigine", "carbamazepine , phenytoin , phenobarbital", "CBZ - ER", "CBZ - ER vs CBZ - IR", "Oxcarbazepine", "placebo .", "VNS", "SPN - 804 ( Oxtellar XRTM", "SPN - 804 or placebo", "placebo , SPN - 804", "ER AED", "SPN - 804", "licarbazepine", "valproate", "lacosamide", "placebo", "carbamazepine ( CBZ )", "perampanel", "immediate - release OXC ( OXC - IR )", "Placebo", "oxcarbazepine ( OXC ),", "MHD", "Oxcarbazepine ( OXC )", "OXC - IR", "CBZ 1", "placebo - controlled", "OXC", "SPN - 804 ( Oxtellar XR )", "Oxtellar XR", "extended - release oxcarbazepine ( Oxtellar XR \u2122)", "CBZ - IR"], "o": ["clinical response and plasma concentration .", "Serious adverse events", "QOLIE - 31 subscales of Cognitive Functioning", "monthly seizure frequency", "Dizziness", "Seizure frequency", "peak plasma concentrations", "trough ( Cmin ) MHD concentrations .", "Adverse event frequency", "\u2265 50 % seizure reduction , proportion of patients seizure free", "percent seizure reduction", "laboratory , vital sign , or ECG abnormality", "patient retention", "to the nervous system", "dizziness , diplopia , nausea , vomiting , abdominal pain", "seizure frequency change", "plasma MHD concentrations", "adverse events", "abnormal sodium value", "mean ( SD ) Cmax of MHD", "apparent oral clearance ( CL / F ), maximum ( Cmax ), and minimum / trough ( Cmin ) concentrations for OXC", "diplopia", "seizure frequency", "pill counts", "median percent seizure reduction", "seizure - free rates", "seizure frequency reduction", "trough MHD concentration", "seizure free", "nausea", "Medication Effects", "responder rate ( proportion", "generalized rash", "seizure freedom", "Clearance", "plasma MHD exposure", "somnolence", "Cmin concentrations", "vomiting", "OXC - IR", "QOLIE - 31 score", "tolerability", "monthly ( 28 - day ) seizure frequency", "plasma concentration", "efficacy , tolerability , and safety", "Dosages of concomitant AEDs and vagal nerve stimulator ( VNS ) settings", "tolerability and effectiveness", "seizure counts", "Adverse event occurrence and discontinuations", "responder rates", "therapeutic success", "Patient Global Impression of Change ( PGIC )", "OXC and MHD concentrations", "treatment - limiting adverse events .", "Treatment - limiting adverse event rates", "Serum sodium levels", "median monthly seizure frequency", "trough MHD concentrations", "QOLIE - 31 subscale scores , total score , and health status score", "specific adverse events", "MHD exposures and peak MHD concentrations", "dizziness", "rate of discontinuations due to adverse events", "treatment - emergent adverse events coded using the Medical Dictionary for Regulatory Affairs ( MedDRA ), neurologic / physical examinations , clinical laboratory values , vital signs , and ECG tracings", "ITT seizure - free rate", "MHD concentration", "Cmin", "seizure frequency reduction ), proportion of patients seizure free , and changes in PGIC and QOLIE - 31 scores .", "normal to lower serum sodium levels", "dizziness , diplopia , somnolence , vomiting , nausea .", "PGIC score changes", "peak plasma MHD concentrations", "overall median Cmin", "symptomatic hyponatremia", "emergency department / inpatient visits", "headache .", "Mean total QOLIE - 31 and subscale scores", "percent seizure frequency change", "mean trough MHD concentrations", "seizure reduction", "seizures", "Median percent seizure frequency reduction", "Quality of Life in Epilepsy ( QOLIE - 31 ) questionnaires", "adverse effects", "number of years since", "ataxia", "dizziness , nausea , somnolence , vomiting , headache , and diplopia \u2013", "seizure - free rates .", "MHD exposure", "hyponatremia", "adherence rates"]}